<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399370</url>
  </required_header>
  <id_info>
    <org_study_id>MDCO-PCS-17-04</org_study_id>
    <nct_id>NCT03399370</nct_id>
  </id_info>
  <brief_title>Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol</brief_title>
  <acronym>ORION-10</acronym>
  <official_title>A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, placebo-controlled, double-blind, randomized study in participants with&#xD;
      ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to&#xD;
      evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s).&#xD;
      The study will be a multicenter study in the United States.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">September 10, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in LDL-C From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-adjusted Percentage Change in LDL-C Levels From Baseline After Day 90 and up to Day 540</measure>
    <time_frame>Baseline, Day 90 to Day 540</time_frame>
    <description>Assessments performed at Baseline, Day 90, Day 540, time-adjusted percent change at Day 540 reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in LDL-C From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540</measure>
    <time_frame>Baseline, Day 90 to Day 540</time_frame>
    <description>Assessments performed at Baseline, Day 90, Day 540, time-adjusted percent change at Day 540 reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Total Cholesterol From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Non-HDL-C From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1561</enrollment>
  <condition>ASCVD</condition>
  <condition>Elevated Cholesterol</condition>
  <arm_group>
    <arm_group_label>Inclisiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inclisiran Sodium</intervention_name>
    <description>Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.</description>
    <arm_group_label>Inclisiran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).</description>
    <arm_group_label>Saline Solution</arm_group_label>
    <other_name>Saline Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participants ≥18 years of age.&#xD;
&#xD;
          2. History of ASCVD (coronary heart disease [CHD], cardiovascular disease [CVD], or&#xD;
             peripheral arterial disease [PAD]).&#xD;
&#xD;
          3. Serum LDL-C ≥1.8 millimole (mmol)/liter (L) (≥70 mg/dL).&#xD;
&#xD;
          4. Fasting triglyceride &lt;4.52 mmol/L (&lt;400 mg/dL) at screening.&#xD;
&#xD;
          5. Participants on statins should be receiving a maximally tolerated dose.&#xD;
&#xD;
          6. Participants not receiving statins must have documented evidence of intolerance to all&#xD;
             doses of at least 2 different statins.&#xD;
&#xD;
          7. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a&#xD;
             stable dose for ≥30 days before screening with no planned medication or dose change&#xD;
             during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New York Heart Association (NYHA) class IV heart failure.&#xD;
&#xD;
          2. Uncontrolled cardiac arrhythmia&#xD;
&#xD;
          3. Uncontrolled severe hypertension&#xD;
&#xD;
          4. Active liver disease&#xD;
&#xD;
          5. Females who are pregnant or nursing, or who are of childbearing potential and&#xD;
             unwilling to use at least 2 methods of highly effective contraception (failure rate&#xD;
             less than 1% per year) (for example, combined oral contraceptives, barrier methods,&#xD;
             approved contraceptive implant, long-term injectable contraception, or intrauterine&#xD;
             device) for the entire duration of the study. Exemptions from this criterion:&#xD;
&#xD;
               1. Women &gt;2 years postmenopausal (defined as 1 year or longer since last menstrual&#xD;
                  period) and more than 55 years of age.&#xD;
&#xD;
               2. Postmenopausal women (as defined above) and less than 55 years of age with a&#xD;
                  negative pregnancy test within 24 hours of randomization.&#xD;
&#xD;
               3. Women who are surgically sterilized at least 3 months prior to enrollment.&#xD;
&#xD;
          6. Males who are unwilling to use an acceptable method of birth control during the entire&#xD;
             study period (such as condom with spermicide).&#xD;
&#xD;
          7. Treatment with other investigational products or devices within 30 days or 5&#xD;
             half-lives of the screening visit, whichever is longer.&#xD;
&#xD;
          8. Treatment (within 90 days of screening) with monoclonal antibodies directed towards&#xD;
             PCSK9&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a&#xD;
        participant's potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Wright, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site 10001-015</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-138</name>
      <address>
        <city>Foley</city>
        <state>Alabama</state>
        <zip>36535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-113</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-058</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-037</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-076</name>
      <address>
        <city>Saraland</city>
        <state>Alabama</state>
        <zip>36571</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-013</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-077</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-136</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-051</name>
      <address>
        <city>Surprise</city>
        <state>Arizona</state>
        <zip>85374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-019</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-004</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-132</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-073</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-050</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-011</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-065</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-150</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-043</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-022</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-033</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821-2134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-105</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-008</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-153</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-044</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-047</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-084</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-155</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-099</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-127</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-119</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-070</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-067</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-139</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-039</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-098</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-080</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-081</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-140</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-142</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-030</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-089</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-116</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-027</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-115</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-048</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-147</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-003</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-104</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-090</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-102</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-123</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239-3513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-038</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-143</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-069</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-137</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-092</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-059</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-158</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-035</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-036</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-082</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1001-020</name>
      <address>
        <city>Sellersburg</city>
        <state>Indiana</state>
        <zip>47172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-040</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-074</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-028</name>
      <address>
        <city>Hutchinson</city>
        <state>Kansas</state>
        <zip>67502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-125</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-108</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-107</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-144</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-041</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-101</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-024</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-095</name>
      <address>
        <city>Grandville</city>
        <state>Michigan</state>
        <zip>49418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-078</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-034</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-018</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-056</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-156</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-007</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-053</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-021</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-112</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-124</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-060</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-055</name>
      <address>
        <city>Raritan</city>
        <state>New Jersey</state>
        <zip>08869</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-054</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-122</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-128</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-042</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-129</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-110</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-063</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-064</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-145</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-046</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-016</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>443311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-120</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-154</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-010</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-134</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-014</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-012</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-141</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45419</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-148</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-017</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-109</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-001</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-006</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-075.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-111</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-133</name>
      <address>
        <city>Pelzer</city>
        <state>South Carolina</state>
        <zip>29669</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-026</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-103</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-146</name>
      <address>
        <city>Athens</city>
        <state>Tennessee</state>
        <zip>37303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-130</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-118</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-100</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-087</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-117</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-009</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-068</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-126</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-031</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-088</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-091</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-061</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-032</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-025</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-057</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-106</name>
      <address>
        <city>Powell</city>
        <state>Texas</state>
        <zip>37849</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-079</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-071</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-083</name>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <zip>78154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-149</name>
      <address>
        <city>Shavano Park</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-045</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-005</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-002</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-052</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-093</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-085</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-094</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-023</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-029</name>
      <address>
        <city>Suffolk</city>
        <state>Virginia</state>
        <zip>23435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10001-114</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <results_first_submitted>July 1, 2020</results_first_submitted>
  <results_first_submitted_qc>September 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2020</results_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inclisiran sodium</keyword>
  <keyword>ASCVD</keyword>
  <keyword>LDL-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03399370/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03399370/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inclisiran</title>
          <description>Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.&#xD;
Inclisiran Sodium: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.</description>
        </group>
        <group group_id="P2">
          <title>Saline Solution</title>
          <description>Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.&#xD;
Placebo: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="781"/>
                <participants group_id="P2" count="780"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="721"/>
                <participants group_id="P2" count="694"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inclisiran</title>
          <description>Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.&#xD;
Inclisiran Sodium: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.&#xD;
Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="781"/>
            <count group_id="B2" value="780"/>
            <count group_id="B3" value="1561"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="333"/>
                    <measurement group_id="B3" value="630"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="484"/>
                    <measurement group_id="B2" value="447"/>
                    <measurement group_id="B3" value="931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.4" spread="8.90"/>
                    <measurement group_id="B2" value="65.7" spread="8.89"/>
                    <measurement group_id="B3" value="66.0" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="478"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="535"/>
                    <measurement group_id="B2" value="548"/>
                    <measurement group_id="B3" value="1083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="653"/>
                    <measurement group_id="B2" value="685"/>
                    <measurement group_id="B3" value="1338"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="781"/>
                    <measurement group_id="B2" value="780"/>
                    <measurement group_id="B3" value="1561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in LDL-C From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.&#xD;
Inclisiran Sodium: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in LDL-C From Baseline to Day 510</title>
          <population>Intent-to-treat (ITT) population</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="781"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.34" lower_limit="-58.35" upper_limit="-54.34"/>
                    <measurement group_id="O2" value="1.30" lower_limit="-1.24" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>LS Mean Difference (95% CI) from Placebo</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-57.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.86</ci_lower_limit>
            <ci_upper_limit>-54.43</ci_upper_limit>
            <estimate_desc>Represents the least squares mean difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time-adjusted Percentage Change in LDL-C Levels From Baseline After Day 90 and up to Day 540</title>
        <description>Assessments performed at Baseline, Day 90, Day 540, time-adjusted percent change at Day 540 reported</description>
        <time_frame>Baseline, Day 90 to Day 540</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-adjusted Percentage Change in LDL-C Levels From Baseline After Day 90 and up to Day 540</title>
          <description>Assessments performed at Baseline, Day 90, Day 540, time-adjusted percent change at Day 540 reported</description>
          <population>Intent-to-treat (ITT) population</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="781"/>
                <count group_id="O2" value="790"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.27" lower_limit="-53.00" upper_limit="-49.54"/>
                    <measurement group_id="O2" value="2.51" lower_limit="0.77" upper_limit="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>LS Mean Difference (95% CI) from Placebo</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-53.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.23</ci_lower_limit>
            <ci_upper_limit>-51.33</ci_upper_limit>
            <estimate_desc>Represents the least squares mean difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in LDL-C From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in LDL-C From Baseline to Day 510</title>
          <population>Intent-to-treat (ITT) population</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="781"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.18" lower_limit="-58.47" upper_limit="-53.90"/>
                    <measurement group_id="O2" value="-2.06" lower_limit="-4.36" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>LS Mean Difference (95% CI) from Placebo</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-54.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.37</ci_lower_limit>
            <ci_upper_limit>-50.88</ci_upper_limit>
            <estimate_desc>Represents the least squares mean difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540</title>
        <description>Assessments performed at Baseline, Day 90, Day 540, time-adjusted percent change at Day 540 reported</description>
        <time_frame>Baseline, Day 90 to Day 540</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540</title>
          <description>Assessments performed at Baseline, Day 90, Day 540, time-adjusted percent change at Day 540 reported</description>
          <population>Intent-to-treat (ITT) population</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="781"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.66" lower_limit="-55.41" upper_limit="-51.92"/>
                    <measurement group_id="O2" value="-0.39" lower_limit="-2.14" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-53.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.75</ci_lower_limit>
            <ci_upper_limit>-50.80</ci_upper_limit>
            <estimate_desc>Represents the least squares mean difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510</title>
          <population>Intent-to-treat (ITT) population</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="781"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.78" lower_limit="-73.88" upper_limit="-65.67"/>
                    <measurement group_id="O2" value="13.52" lower_limit="9.28" upper_limit="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-83.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-89.25</ci_lower_limit>
            <ci_upper_limit>-77.34</ci_upper_limit>
            <estimate_desc>Represents the least squares mean difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Total Cholesterol From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Total Cholesterol From Baseline to Day 510</title>
          <population>Intent-to-treat (ITT) population</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="781"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.56" lower_limit="-35.09" upper_limit="-32.03"/>
                    <measurement group_id="O2" value="-0.42" lower_limit="-1.95" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.30</ci_lower_limit>
            <ci_upper_limit>-30.97</ci_upper_limit>
            <estimate_desc>Represents the least squares mean difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510</title>
          <population>Intent-to-treat (ITT) population</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="781"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.81" lower_limit="-46.52" upper_limit="-43.10"/>
                    <measurement group_id="O2" value="-1.72" lower_limit="-3.46" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-43.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.50</ci_lower_limit>
            <ci_upper_limit>-40.67</ci_upper_limit>
            <estimate_desc>Represents the least squares mean difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Non-HDL-C From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Non-HDL-C From Baseline to Day 510</title>
          <population>Intent-to-treat (ITT) population</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="781"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.41" lower_limit="-49.44" upper_limit="-45.38"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-2.08" upper_limit="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-47.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.25</ci_lower_limit>
            <ci_upper_limit>-44.47</ci_upper_limit>
            <estimate_desc>Represents the least squares mean difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inclisiran</title>
          <description>Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.&#xD;
Inclisiran Sodium: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.</description>
        </group>
        <group group_id="E2">
          <title>Saline Solution</title>
          <description>Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.&#xD;
Placebo: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Nodal arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Ectopic hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ophthalmic vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Larger intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cavernous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Diverticultis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Periotinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cardiac contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cardiac valve replacement complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Chemical burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Incisional hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Occupational exposure to product</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Post procedural hawmorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Fracture malunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Breast cancer stage 1</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Gastrointestinal lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Liposarcoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Myelodyplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Demetia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Spinal subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Status migrainosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="219" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="781"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice-President, Regulatory Operations</name_or_title>
      <organization>The Medicines Company</organization>
      <phone>973-985-0597</phone>
      <email>frank.bosley@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

